Brand against brand · semaglutide and liraglutide
Wegovy vs Saxenda
From the two FDA labels, read Published by PepVault
Wegovy is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Saxenda is liraglutide, a GLP-1 receptor agonist, from Novo Nordisk.
FDA approved Wegovy for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH. Saxenda is approved for weight loss and keeping it off, in adults and in children 12 and older with obesity.
Label against label
| Compared | Wegovy | Saxenda |
|---|---|---|
| Active ingredient | semaglutide | liraglutide |
| Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maker | Novo Nordisk | Novo Nordisk |
| Approved for | Weight reduction; heart risk with obesity; MASH (injection) | Weight reduction (adults and children 12 and up) |
| Forms | Single-dose pen; Single-dose syringe; FlexTouch pen; Tablet | Prefilled pen |
| How often | once a week or once a day | once a day |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 0.6 mg a day |
| Top dose on the label | 7.2 mg a week (injection); 25 mg a day (tablets) | 3 mg a day |
| Most reported side effect | Nausea, 44% on 2.4 mg (placebo 16%) | Nausea, 39.3% on Saxenda (placebo 13.8%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2021 | 2014 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Wegovy injection, once a week
Wegovy tablets, once a day
Saxenda, once a day

A missed dose, on each label
- Wegovy: For a missed injection, the label looks at the next scheduled dose: more than 2 days away, take the missed one as soon as possible; less than 2 days away, skip it. Missing 2 or more weeks in a row means starting the climb again from a lower dose.
- Saxenda: If a day is missed, the label goes on with the next scheduled dose and never doubles up.
The trial evidence
Questions
What is the difference between Wegovy and Saxenda?
Wegovy is semaglutide, a GLP-1 receptor agonist; Saxenda is liraglutide, a GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.
What are Wegovy and Saxenda approved for?
Wegovy is approved for weight loss and keeping it off, lowering heart risk in adults with heart disease and excess weight, and (the injection) the liver disease MASH. Saxenda is approved for weight loss and keeping it off, in adults and in children 12 and older with obesity.
How often are Wegovy and Saxenda taken?
Wegovy is taken once a week or once a day, as an injection or a tablet; Saxenda once a day, as an injection.
What are the dose ranges of Wegovy and Saxenda?
On their labels, Wegovy runs 0.25 mg to 7.2 mg once a week or 1.5 mg to 25 mg once a day, and Saxenda 0.6 mg to 3 mg once a day. A prescriber sets the actual dose.
What is the most common side effect of Wegovy and Saxenda?
On Wegovy’s label: nausea, 44% on 2.4 mg (placebo 16%). On Saxenda’s: nausea, 39.3% on Saxenda (placebo 13.8%).
Sources
- WEGOVY (semaglutide) injection, for subcutaneous use, and WEGOVY (semaglutide) tablets, for oral use, FDA label on DailyMed (version 19, published Jun 30, 2026; read Nov 18, 2026)
- SAXENDA (liraglutide) injection, for subcutaneous use, FDA label on DailyMed (version 22, published Jun 15, 2026; read Nov 18, 2026)
- Drugs@FDA, NDA 215256 (Wegovy, the injection; application first approved 2021)
- Drugs@FDA, NDA 218316 (Wegovy, the tablets; application first approved 2025)
- Drugs@FDA, NDA 206321 (Saxenda, the injection; application first approved 2014)
PepVault is not affiliated with Novo Nordisk. Wegovy is a trademark of its owner. Saxenda is a trademark of its owner.